Zipalertinib demonstrates clinical benefit in EGFR ex20ins NSCLC, Cullinan Therapeutics reports

Zipalertinib demonstrates clinical benefit in EGFR ex20ins NSCLC, Cullinan Therapeutics reports
Cullinan Therapeutics unveils zipalertinib results

Cullinan Therapeutics announced new clinical data showing that zipalertinib achieved clinically meaningful intracranial antitumor activity in patients with EGFR exon 20 insertion or uncommon EGFR-mutated non-small cell lung cancer (NSCLC) with active central nervous system metastases.

The results, part of a partnership with Taiho Oncology, are set to be presented at ESMO26. The findings highlight ongoing research efforts into therapies targeting difficult-to-treat mutations in NSCLC.

Cullinan Therapeutics recently began an NDA submission with the FDA for zipalertinib plus chemotherapy in NSCLC in partnership with Taiho Oncology, according to a previous company announcement. The company has also outlined fourth quarter 2026 milestones focused on advancing its immunology and oncology T cell engager portfolio, as detailed in a recent pipeline update. These initiatives reflect Cullinan's continued efforts to develop targeted cancer therapies.

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.